David Walsey
Investor Relations Contact at MEI PHARMA, INC.
David Walsey active positions
Companies | Position | Start | End |
---|---|---|---|
MEI PHARMA, INC. | Investor Relations Contact | 2018-01-31 | - |
Public Communications Contact | 2018-01-31 | - |
Career history of David Walsey
Former positions of David Walsey
Companies | Position | Start | End |
---|---|---|---|
ARENA PHARMACEUTICALS | Public Communications Contact | 2004-12-31 | 2008-12-31 |
Maxim Pharmaceuticals, Inc. | Public Communications Contact | - | - |
ALDER BIOPHARMACEUTICALS, INC. | Investor Relations Contact | - | - |
Corporate Officer/Principal | 2015-10-31 | - | |
SAREPTA THERAPEUTICS, INC. | Public Communications Contact | - | - |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Investor Relations Contact | - | - |
Training of David Walsey
New York University School of Law | Graduate Degree |
Brooklyn Law School | Graduate Degree |
Franklin & Marshall College | Undergraduate Degree |
Statistics
International
United States | 10 |
Operational
Public Communications Contact | 4 |
Investor Relations Contact | 3 |
Graduate Degree | 2 |
Sectoral
Health Technology | 7 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
SAREPTA THERAPEUTICS, INC. | Health Technology |
MEI PHARMA, INC. | Health Technology |
Private companies | 4 |
---|---|
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Maxim Pharmaceuticals, Inc. | Health Technology |
- Stock Market
- Insiders
- David Walsey
- Experience